Brief Report: Evaluating Early-Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening

Matthew T Warkentin; Martin C Tammemägi; Erik Vakil; Eric L R Bedard; Winson Y Cheung; Darren R Brenner; Alain Tremblay

doi:10.1016/j.jtho.2024.12.025

Brief Report: Evaluating Early-Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening

J Thorac Oncol. 2024 Dec 30:S1556-0864(24)02546-2. doi: 10.1016/j.jtho.2024.12.025. Online ahead of print.

Authors

Matthew T Warkentin¹, Martin C Tammemägi², Erik Vakil³, Eric L R Bedard⁴, Winson Y Cheung¹, Darren R Brenner¹, Alain Tremblay⁵

Affiliations

¹ Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
² Department of Health Sciences, Brock University, St. Catharines, ON, Canada.
³ Department of Respirology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
⁴ Department of Surgery, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.
⁵ Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address: [email protected].

PMID: 39743140
DOI: 10.1016/j.jtho.2024.12.025

Abstract

Introduction: Older individuals have an elevated lung cancer risk but may also have significant comorbidities that preclude curative treatment options and limit the survival benefits of screening. The objective of this study was to assess early-stage lung cancer survival patterns among those at the upper age limit for screening and identify older individuals who have potential to benefit from for lung cancer screening.

Methods: We identified all early stage (I or II) lung cancers diagnosed in Alberta, Canada between 2010 and 2020. Overall survival (OS) was based on the time from the date of lung cancer diagnosis until the date of death (from any cause) or censoring. We estimated OS using the Kaplan-Meier method. We present OS with 95% confidence intervals (CI) for each age group and sex and stratified by presence of comorbidities (Charlson Comorbidity Index) and receipt of surgery.

Results: There were 6,401 early-stage lung cancers (71% stage I, 29% stage II) of which 43% and 57% were among males and females, respectively. For females, the five-year OS was 54.7% (CI: 50.6-58.8), 47.2% (CI: 42.7-51.7) and 33.7% (CI: 28.4-38.9) for ages 70-74, 75-79, and 80-84, respectively. For males, five-year OS was 47.7% (CI: 43.1-52.3), 38.0% (CI:33.2-42.8), and 24.2% (CI: 19.2-29.3) for ages 70-74, 75-79 and 80-84, respectively. Across all age groups, the five-year OS was higher for those with fewer comorbidities and for those who received surgery as part of their treatment strategy, usually surpassing that in younger cohorts with more comorbidities or who did not receive surgical treatment.

Conclusions: Age limits for lung cancer screening should consider comorbidity and fitness for curative treatment since these can significantly influence the survival following diagnosis and treatment of early lung cancer.